This summer, the chief coding and reimbursement body in the United States will decide whether labs that perform molecular-diagnostic tests will receive a new roster of billing codes, according to a person familiar with the task. If approved, the updated current procedural terminology, or CPT, will likely lower reimbursement hurdles and embolden reference labs to employ more genotyping and gene-expression technologies.